StockData
Immunome Inc. logo

Immunome Inc. (IMNM) stock

IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$17.18−0.43 (-2.44%)

Close on Nov 17, 2026Market cap $1.95BP/E –Yield –

Immunome operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Immunome's operating cash flow for the twelve months ending Mar 31, 2026 was -$196.50M. For fiscal 2025 it was -$190.92M. The highest annual figure on record is -$7.57M in fiscal 2023.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$190.92M–
FY2024Dec 31, 2024-$110.79M–
FY2023Dec 31, 2023-$7.57M–
FY2022Dec 31, 2022-$28.69M–
FY2021Dec 31, 2021-$18.23M–
FY2020Dec 31, 2020-$12.13M–
FY2019Dec 31, 2019-$9.60M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026-$58.64M–
Q4 FY2025Dec 31, 2025-$47.95M–
Q3 FY2025Sep 30, 2025-$40.51M–
Q2 FY2025Jun 30, 2025-$49.40M–
Q1 FY2025Mar 31, 2025-$53.06M–
Q4 FY2024Dec 31, 2024-$42.06M–
Q3 FY2024Sep 30, 2024-$34.17M–
Q2 FY2024Jun 30, 2024-$23.40M–
Q1 FY2024Mar 31, 2024-$11.17M-146.2%
Q4 FY2023Dec 31, 2023-$17.46M–
Q3 FY2023Sep 30, 2023-$8.61M–
Q2 FY2023Jun 30, 2023-$5.67M–
Q1 FY2023Mar 31, 2023$24.17M–
Q4 FY2022Dec 31, 2022-$6.68M–
Q3 FY2022Sep 30, 2022-$7.57M–
Q2 FY2022Jun 30, 2022-$8.06M–
Q1 FY2022Mar 31, 2022-$6.38M–
Q4 FY2021Dec 31, 2021-$6.81M–
Q3 FY2021Sep 30, 2021-$4.15M–
Q2 FY2021Jun 30, 2021-$3.74M–
Q1 FY2021Mar 31, 2021-$3.54M–
Q4 FY2020Dec 31, 2020-$6.06M–
Q3 FY2020Sep 30, 2020-$2.53M–
Q2 FY2020Jun 30, 2020-$1.48M–
Q1 FY2020Mar 31, 2020-$2.06M–
Q4 FY2019Dec 31, 2019-$2.58M–

More Immunome figures

See a number that looks wrong?